Early detection of transformation to BPDCN in a patient with MDS. – PubMed – NCBI
Exp Hematol Oncol. 2018 Oct 6;7:26. doi: 10.1186/s40164-018-0117-6. eCollection 2018. Case Reports
Related Articles
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
Blood Cancer Journal – Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
Treatment patterns and blood count control in 10,112 patients with polycythemia vera
Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contribute to morbidity and mortality.This retrospective study describes treatment patterns and…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL
Abstract. We used single-cell genomics to characterize a patient with T-cell acute lymphoblastic leukemia treated in the Children’s Oncology Group AALL0434
Understanding Prognostic versus Predictive Biomarkers
A variety of factors influence a patient’s clinical outcome, including intrinsic characteristics of the patient, disease, or medical condition, and the effects of any treatments…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
Leukemia – The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX-531 in combination with venetoclax (CPX + VEN) was tolerable and effective in…
A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX-531 in combination with venetoclax (CPX + VEN) was tolerable and effective in…